Core Insights - The stock and mixed funds achieved a positive return of 70.27% on December 8, with 243 funds returning over 5% and 472 funds experiencing a net value drawdown exceeding 1% [1][2] Fund Performance - The Shanghai Composite Index rose by 0.54% to close at 3924.08 points, while the Shenzhen Component Index increased by 1.39%, the ChiNext Index by 2.60%, and the STAR 50 Index by 1.86% [1] - The top-performing sectors included telecommunications, comprehensive, and electronics, with increases of 4.79%, 3.03%, and 2.60% respectively. Conversely, coal, oil and petrochemicals, and food and beverage sectors saw declines of 1.43%, 0.84%, and 0.78% respectively [1] - The average net value growth rate for stock and mixed funds on December 8 was 0.80% [1] Top Funds - The fund with the highest net value growth rate was Guorong Rongxin Consumer Select Mixed C, achieving a growth rate of 10.01%. Other notable funds included Guorong Rongxin Consumer Select Mixed A (10.00%), and Guoshou Anbao Strategy Selected Mixed A (9.14%) [2] - Among the funds with a net value growth rate exceeding 5%, 142 were equity funds, 41 were flexible allocation funds, and 34 were index equity funds [2] Drawdown Analysis - A total of 472 funds experienced a drawdown exceeding 1%, with the largest drawdown recorded by Huatai-PB Hong Kong Stock Connect Medical Selected Mixed Initiated C, which saw a decline of 2.40% [2][4] - Other funds with significant drawdowns included Huatai-PB Hong Kong Stock Connect Medical Selected Mixed Initiated A (-2.40%), and Yin Hua Fu Li Selected Mixed C (-2.32%) [4]

本篇我们将视角转向中资公募机构。作为香港资本市场的重要参与者，中资公募基金机构近年来发展迅 速，依托母公司强大的投研能力、跨境业务协同机制以及离岸人民币市场的独特优势，逐步构建起具有 本土化深度与国际化广度兼备的竞争力。 香港处理着全球约80%的人民币支付业务，是最大的人民币离岸中心。中资公募机构凭借这一区位优 势，结合QFII、RQFII、沪深港通、债券通、跨境理财通等政策工具，形成了"境内—香港"资金、客户 与资产的高效双向流动机制，打造出低成本、高效率的跨境一体化平台。 以下，我们选取六家在香港市场具有代表性的中资公募机构，从产品体系、投资策略、业务特色、适用 场景等维度进行系统梳理，以供投资者参考。 一、中银国际资管（BOCI AM） 关键词：银行系、全币种、港股通医药冠军 生态位：香港最大银行系资管，人民币清算量市占率35%，母公司中银香港坐拥200万零售户口。 产品线：80余只公募，货—债—股—多资产"闭环"，人民币、美元、港元三币种一键切换。 年度黑马：中银港股通医药混合发起A，2025年以来收益+102%，同类第一，规模从年初4亿飙至87亿 港元。 在之前文章中，我们系统梳理了九家具有代表性的 ...

Core Viewpoint - The A-share market has shown a "slow bull" trend in the first three quarters of this year, with significant contributions from the TMT (Technology, Media, and Telecommunications) sector, particularly in AI, robotics, and semiconductors. Active equity fund managers who actively position in new directions have performed well, but the volatility in popular sectors and events like the "tariff shock" in early April have impacted their ability to manage drawdowns, affecting investor experiences [4]. Summary by Category Overall Performance of Active Equity Fund Managers - In the first three quarters of this year, there are 1,698 active equity fund managers with an average return of 34.08% and a median return of 30.45%. The average drawdown is -13.93%, with a median of -13.05% [4][5]. - Fund managers managing over 100 billion yuan have the highest median returns at 36.79%, but also face larger drawdowns [5]. Performance by Management Scale - **Over 100 Billion Yuan**: 80 managers, median return 36.79%, median drawdown -14.13%. Top performers include Zhang Wei from Huatai-PineBridge and Ge Lan from China Europe Fund, both heavily invested in the pharmaceutical sector [6][7]. - **50-100 Billion Yuan**: 130 managers, median return 35.28%, median drawdown -13.28%. Top performers include Zheng Ning from Zhongyin Fund, with a return of 95.01% [9][10]. - **20-50 Billion Yuan**: 275 managers, median return 32.82%, median drawdown -13.08%. Top performers include Dan Lin from Yongying Fund, with a return of 97.40% [13][14]. - **Below 20 Billion Yuan**: 1,213 managers, median return 29.46%, median drawdown -12.95%. Top performers include Wang Chao from Fortune Fund, with a return of 93.31% [16]. Notable Fund Managers - **Zhang Wei**: Achieved a return of 69.62% with a maximum drawdown of -10.01%, managing six funds [7][8]. - **Zheng Ning**: Focused on innovative drugs, achieving a return of 95.01% with a maximum drawdown of -13.06% [10][12]. - **Dan Lin**: Achieved a return of 97.40% with a maximum drawdown of -12.88% [14]. - **Zhao Longlong**: Managed to achieve a return of 62.08% with the smallest drawdown of -9.51% among his peers [15]. Investment Focus - Fund managers are increasingly focusing on sectors such as innovative pharmaceuticals and high-end medical devices, with a notable emphasis on the potential of Chinese innovative drugs in international markets [8][10].

Core Insights - The A-share market has shown a "slow bull" trend in the first three quarters of this year, with significant contributions from the TMT sector, particularly in AI, robotics, and semiconductors [1] - Active equity fund managers have performed well, but the volatility in popular sectors and events like the "tariff shock" in early April have impacted their ability to manage drawdowns [1] - The average return for active equity fund managers this year is 34.08%, with a median return of 30.45%, while the average drawdown is -13.93% and the median drawdown is -13.05% [1][3] Fund Manager Performance by Management Scale Over 100 Billion - Among the 80 active equity fund managers with over 100 billion in management scale, the median return is 36.79% and the median drawdown is -14.13% [3] - Notable fund managers include Zhang Wei from Huatai-PineBridge and Ge Lan from China Europe Fund, both heavily invested in the pharmaceutical sector [3][4] 50-100 Billion - In the 50-100 billion category, 130 fund managers have a median return of 35.28% and a median drawdown of -13.28% [8] - The top performer is Zheng Ning from Bank of China Fund, achieving a return of 95.01% with a maximum drawdown of -13.06% [9] 20-50 Billion - For managers with 20-50 billion in assets, the median return is 32.82% and the median drawdown is -13.08% [10] - The top three fund managers include Dan Lin from Yongying Fund, Jin Xiaofei from Penghua Fund, and Zhao Longlong from Morgan Fund [12] Below 20 Billion - In the category of managers with less than 20 billion, the median return is 29.46% and the median drawdown is -12.95% [15] - The top three fund managers are Wang Chao from Fortune Fund, Qi Zhen from Huabao Fund, and Liu Haixiao from Haifutong Fund [15]

Core Viewpoint - The article highlights the performance of equity funds in the A-share market, noting that many funds have reached historical highs in net value as of July 2025, driven by a strong upward trend in major stock indices [4][5]. Group 1: Performance of Equity Funds - As of the end of July 2025, 1,985 equity funds (established for over a year) reached historical highs in net value [4]. - The Shanghai Composite Index rose by 3.74%, the Shenzhen Component Index by 5.20%, and the ChiNext Index by 8.14% in July 2025 [4]. - Among the top-performing funds from January to July 2025, 834 funds were analyzed, with 74% meeting the criteria for the top 20 performers [5]. Group 2: Top Performing Funds - The top three funds for the period of January to July 2025 are: 1. Zhongyin Hong Kong Stock Connect Medical Mixed Fund A (Code: 020397) with a return of 113.51% [5][10]. 2. Yongying Medical Innovation Selected Mixed Fund A (Code: 015915) with a return of 113.30% [5]. 3. Guangfa Growth Leading One-Year Holding Mixed Fund A (Code: 016243) with a return of 97.33% [5]. - The Zhongyin fund had a scale of approximately 139 million yuan as of the second quarter of 2025 and has achieved a cumulative return of 88.72% since its inception [10][11]. Group 3: Recent Year Performance - In the past year, all top 20 funds have achieved over 100% returns, with six being North Exchange theme funds and five being medical theme funds [12]. - The top three funds for the past year are: 1. CITIC Construction North Exchange Selected Two-Year Open Mixed Fund A (Code: 016303) with a return of 202.70% [12][17]. 2. Huitianfu North Exchange Innovation Selected Two-Year Open Mixed Fund A (Code: 014279) with a return of 152.49% [12]. 3. Wanjia North Exchange Wise Selection Two-Year Open Mixed Fund A (Code: 014277) with a return of 139.98% [12]. Group 4: Three-Year Performance - The top three funds over the past three years are: 1. Huitianfu North Exchange Innovation Selected Two-Year Open Mixed Fund A (Code: 014279) with a return of 135.25% [19][24]. 2. Jia Shi Mutual Fund Selected Stock A (Code: 006603) with a return of 120.26% [19]. 3. Wanjia North Exchange Wise Selection Two-Year Open Mixed Fund A (Code: 014277) with a return of 108.56% [19]. Group 5: Five-Year Performance - The top three funds over the past five years are: 1. Jinyuan Shun'an Yuanqi Flexible Allocation Mixed Fund (Code: 004685) with a return of 262.69% [26][31]. 2. Dongwu New Trend Value Line Mixed Fund (Code: 001322) with a return of 183.15% [26]. 3. Dongwu Mobile Internet Mixed A (Code: 001323) with a return of 178.89% [26].

Core Viewpoint - The article discusses the recent performance of the A-share market, highlighting a recovery in the Shanghai Composite Index after a political bureau meeting that released positive signals for the economy and investment opportunities in the innovative pharmaceutical sector [1][2][8]. Group 1: A-share Market Performance - The A-share market experienced a pullback but rebounded in the afternoon, with the Shanghai Composite Index closing in the green, reaching a new high for the year [2][7]. - The market showed significant structural differentiation, with consumer and banking sectors rising while technology and new energy sectors faced declines [6][7]. - The trading volume exceeded 1.84 trillion yuan, indicating active market participation [5]. Group 2: Political Bureau Meeting Insights - The Central Political Bureau meeting emphasized the need to "stably resolve local government debt risks" and introduced a roadmap for "clearing financing platforms," alleviating systemic risk concerns [9]. - The meeting also highlighted the importance of stimulating domestic demand and implementing actions to boost consumption, positively impacting sectors like tourism, retail, and food and beverage [10]. - A focus on technological innovation was reiterated, aiming to foster new competitive industries and integrate technological advancements with industrial development [12]. Group 3: Investment Opportunities in Innovative Pharmaceuticals - A significant number of funds have achieved over 100% returns this year, particularly in the innovative pharmaceutical sector, with several funds listed showing substantial year-to-date performance [17]. - Fund managers suggest a cautious yet optimistic approach to the innovative pharmaceutical sector, advising investors to match risk and return expectations and avoid excessive chasing of high-flying stocks [18][19]. - Key guidelines for selecting funds include focusing on long-term performance stability, understanding investment strategies, and aligning with personal risk preferences [20].

Group 1 - The core viewpoint of the report indicates that the construction materials and coal industries performed well during the period, with the Shanghai Composite Index rising by 1.67% and the Shenzhen Component Index increasing by 2.33% [2][9] - In the recent 12 periods, the comprehensive and pharmaceutical industries showed strong performance, suggesting potential investment opportunities in these sectors [9] - Active equity funds focusing on electronics and coal industries also demonstrated superior performance during this period [14] Group 2 - Among various fund types, actively managed stock funds increased by 1.55%, while mixed funds rose by 1.63%, and bond funds saw a slight decline of 0.16% [2] - The average return of convertible bond funds was notably high at 12.46% year-to-date, indicating a strong performance in this category [17] - QDII funds, particularly those focused on Asia-Pacific and emerging markets, led the performance with an increase of 2.56% during the period [19][21]

Core Insights - The innovative drug sector has seen significant growth this year, with the innovative drug index achieving a cumulative increase of 73.62% year-to-date, and over a quarter of its constituent stocks doubling in price [2][5] - Despite strong performance, there is a notable divergence in fund flows, with some high-performing funds experiencing substantial increases in scale while others face significant reductions [3][4] Fund Performance - Over 98% of pharmaceutical-related theme funds have reported gains this year, with 72 products seeing increases exceeding 50%. Notable performers include Changcheng Pharmaceutical Industry Select Mixed Fund A, which has achieved a return of 116.12% [1][2] - Conversely, some funds have reported negative returns, such as Taikang Medical Health Stock Fund A, which has a year-to-date return of -3.41% [2][3] Fund Flow Dynamics - There has been a significant inflow of funds into certain high-performing products, with some funds experiencing scale increases of over 30 times in a single quarter. For instance, Changcheng Pharmaceutical Industry Select Mixed Fund A's scale surged from 0.36 million to 11.32 million [3][4] - However, more than 30% of funds with returns exceeding 30% have seen a decrease in scale, indicating a complex investor sentiment [3][6] Investor Behavior - Investor behavior reflects a cautious approach, with some choosing to "take profits" amid concerns over short-term volatility. This has led to a significant outflow of over 6.7 billion from related pharmaceutical theme products in the past month [5][6] - Fund managers suggest that the current market adjustment may present a good opportunity for long-term investment in the innovative drug sector, which is believed to be undergoing a significant transformation [6][7] Market Outlook - The innovative drug sector is expected to continue attracting attention, with fund managers focusing on clinical data, overseas licensing, and domestic sales growth as key areas for investment [7]

Market Overview - The market has recently experienced an upward trend, reaching 3500 points, with active trading volumes around 1.5 trillion [1] - The technology growth sector has shown greater elasticity, with frequent rotation of market hotspots [1] Fund Performance - Active equity funds have outperformed index funds, with several funds showing remarkable performance [1] - A list of funds that have doubled in value over the past year has been compiled, focusing on active equity funds [2] Notable Funds - **Zhongou Digital Economy Mixed Fund A**: Achieved a daily increase of 7.02%, entering the "doubling fund" category, driven by Nvidia's approval to export H20 chips [3] - **Yongying Advanced Manufacturing Smart Selection Mixed Fund A**: Focuses on AI infrastructure and applications, with a high concentration in the AI sector [5] - **Ping An Advanced Manufacturing Theme Stock Fund A**: Managed by a former traditional automotive engineer, showing a diversified portfolio across various sectors [6] - **Zhonghang Trend Navigation Mixed Fund A**: Also emphasizes investment in the robotics industry, with a focus on machine learning and AI applications [7] Fund Holdings - **Zhongou Digital Economy Mixed Fund A**: Major holdings include Zhongji Xuchuang, with a 10.18% allocation, and other tech stocks [4] - **Ping An Advanced Manufacturing Theme Stock Fund A**: The top ten holdings account for only 36.90% of the portfolio, indicating a diversified approach [6] - **Zhonghang Trend Navigation Mixed Fund A**: Similar to other funds, it has a strong focus on the robotics sector, awaiting further updates from the second quarter report [7] Future Outlook - Fund managers express confidence in the potential of Chinese companies in the global AI landscape, anticipating significant innovations in core technologies [5]

Core Viewpoint - The introduction of the "Several Measures to Support the High-Quality Development of Innovative Drugs" by the National Medical Insurance Administration and the National Health Commission marks the beginning of a full lifecycle policy support phase for China's innovative drug industry, accelerating its development [1] Group 1: Policy Support and Industry Development - The new policy includes 16 specific measures aimed at supporting innovative drug development across various dimensions such as research and development, medical insurance access, and clinical application [1] - Since the mention of "innovative drugs" in the 2024 Government Work Report, a series of supportive policies have been released, covering financing, drug approval, pricing, and insurance payment [1] - Systematic support is expected to help domestic pharmaceutical companies transition from a combination of imitation and innovation to global original research and development [1] Group 2: Market Performance and Investment Opportunities - The Hong Kong Stock Market's Hang Seng Innovative Drug Index has seen a year-to-date increase of 68.71% as of July 9, 2025, with a current TTM price-to-earnings ratio of 29.44, indicating potential for valuation recovery [2] - In 2024, Hong Kong innovative drug companies achieved revenue of 48.53 billion yuan, a year-on-year growth of 17.3%, with several leading firms turning profitable in 2025 [2] - The total amount of overseas licensing transactions by Chinese innovative drug companies reached 45.5 billion USD from January to May 2025, surpassing the total for the first half of 2024, validating the "research in China, monetization globally" business model [2] Group 3: Fund Performance - The Zhongyin Hong Kong Stock Connect Medical Mixed Fund has performed well, ranking 1st out of 41 similar products over the past year [2] - Zhongyin Innovation Medical Mixed A Fund has also shown strong performance, ranking 3rd out of 83 similar funds over the past year [3] - The overall market capitalization of the innovative drug sector is approximately 3 trillion yuan, presenting a favorable risk-reward ratio for investors [3]